Fighting Cancer ... with Science
October 10, 2013
“Programmed Sickle Cells Augment Delivery of Cytotoxics to Tumors"...Data Highlighted on Cover of Journal of Controlled Release (impact factor:8) with Editorial by Editor Professor K. Kwon of Purdue University
Dr. Terman Talks About “Drug-Loaded Sickle Cells in Cancer Treatment”
with Joan Hamburg on WOR Radio, New York
January 9. 2013
"Sickle Cells Target Cytotoxics to Hypoxic Tumor Micorvessels and Potentiate a Tumoricidal Response" published in PLOS ONE (Impact factor:14)
Terman et al., PLOS ONE.pdf
Adobe Acrobat document [2.0 MB]
CBS TV News: Dr.David Terman discusses Sickle Cells for Treatment for Drug Resistant Breast Cancer with
Dr. Max Gomez below
Video Demonstration of a sickle cells in action against a highly drug resistant breast tumor. After injection of labelled sickle cells (SRBCs) the SSRBCs stick to tumor blood vessel walls where they cluster and block blood flow. In contrast, normal red blood cells (NRBCs) pass freely through the tumor blood vessels without sticking or blocking blood flow.
Krista Hoff discusses Terman et al., paper in PLOS ONE 2013 showing sickle cells targeting and killing hypoxic niches within drug resistant 4T1 mammary carcinoma in mice.
About Jenomic Research Institute
Jenomic is a biotech company devoted to developing novel drugs and drug vehicles for treatment of cancer. These efforts are supported by a raft of peer- reviewed publications and worldwide patents/patent applications.
The research team is led by David S. Terman, MD, an emeritus member of the American Society of Clinical Investigation (academia's physician-scientist honor society), former Professor of Medicine, Microbiology and Immunology and Founding Director of Cancer Biology Program at Baylor College of Medicine. He is currently Adjunct Professor of Biochemistry and Molecular Biology at UAB in Birmingham. Dr. Terman is cited in Who's Who in America 2008-2013